rare-disease-drugs

Stat

FDA Leadership Changes Prompt Concerns Among Rare Disease Drug Developers

Drug industry executives and an academic expert discussed the effects of recent FDA personnel changes on rare disease drug development at a conference in San Francisco on May 20, 2026. They expressed uncertainty about clinical trial requirements and investor reactions.

1 source